心脏术后停用丙泊酚镇静时单剂昂丹司琼预防PONV的随机对照试验
该随机对照试验纳入≥19岁无PONV史的心脏手术患者,比较停用术后丙泊酚镇静时单剂昂丹司琼4 mg与安慰剂对拔管后24小时内PONV的影响。两组头痛和室性心律失常发生率无显著差异。结论支持心脏手术患者拔管前停用丙泊酚镇静时常规给予昂丹司琼预防PONV。
要点
- 心脏术后停丙泊酚时单剂昂丹司琼4 mg可降低拔管后24小时PONV发生率。
- 昂丹司琼组PONV 43% vs 安慰剂组61%,RR 0.70,NNT 5.5。
- 两组术后头痛和室性心律失常发生率无显著差异。
核心结论
- 心脏手术患者拔管前停用术后丙泊酚镇静时给予单剂昂丹司琼4 mg可降低拔管后24小时内PONV发生率。
研究设计与样本
- 随机对照试验,纳入≥19岁无PONV史、需体外循环的择期或紧急心脏手术患者,昂丹司琼组77例、安慰剂组82例。
临床怎么用
- 心脏手术患者拔管前停用术后丙泊酚镇静时,可考虑常规给予单剂昂丹司琼4 mg预防PONV。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative nausea and vomiting (PONV) is a common occurrence after cardiac surgery. However, in contrast to other surgical populations, routine PONV prophylaxis is not a standard of care in cardiac surgery. We hypothesized that routine administration of a single prophylactic dose of ondansetron (4 mg) at the time of stopping postoperative propofol sedation before extubation in the cardiac surgery intensive care unit would decrease the incidence of PONV. METHODS: With institutional human ethics board approval and written informed consent, we conducted a randomized controlled trial in patients ≥19 years of age with no history of PONV undergoing elective or urgent cardiac surgery procedures requiring cardiopulmonary bypass. The primary outcome was the incidence of PONV in the first 24 hours postextubation, compared by the χ test. Secondary outcomes included the incidence and times to first dose of rescue antiemetic treatment administration, the incidence of headaches, and the incidence of ventricular arrhythmias. RESULTS: PONV within the first 24 hours postextubation occurred in 33 of 77 patients (43%) in the ondansetron group versus 50 of 82 patients (61%) in the placebo group (relative risk, 0.70 [95% confidence interval {CI}, 0.51-0.95]; absolute risk difference, -18% [95% CI, -33 to -2]; number needed to treat, 5.5 [95% CI, 3.0-58.4]; χ test, P = .022). Kaplan-Meier "survival" analysis of the times to first rescue antiemetic treatment administration over 24 hours indicated that patients in the ondansetron group fared better than those in the placebo group (log-rank [Mantel-Cox] test; P = .028). Overall, 32 of 77 patients (42%) in the ondansetron group received rescue antiemetic treatment over the first 24 hours postextubation versus 47 of 82 patients (57%) in the placebo group (relative risk, 0.73 [95% CI, 0.52-1.00]; absolute risk difference, -16% [95% CI, -31 to 1]); P = .047. There were no significant differences between the groups in the incidence of postoperative headache (ondansetron group, 5 of 77 patients [6%] versus placebo group, 4 of 82 patients [5%]; Fisher exact test; P = .740) or ventricular arrhythmias (ondansetron group, 2 of 77 patients [3%] versus placebo group, 4 of 82 patients [5%]; P = .68). CONCLUSIONS: These findings support the routine administration of ondansetron prophylaxis at the time of discontinuation of postoperative propofol sedation before extubation in patients following cardiac surgery. Further research is warranted to optimize PONV prophylaxis in cardiac surgery patients.
引用
- Wang EHZ, Sunderland S, Edwards NY, et al. A Single Prophylactic Dose of Ondansetron Given at Cessation of Postoperative Propofol Sedation Decreases Postoperative Nausea and Vomiting in Cardiac Surgery Patients: A Randomized Controlled Trial. Anesth Analg. 2020. PMID: 32925337. doi:10.1213/ANE.0000000000004730
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。